Name: MC-VC-PABC-Aur0101
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

Pelidotin

IUPAC Name

[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[1-[[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]carbamate

Canonical SMILES

CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C)(C)NC(=O)OCC4=CC=C(C=C4)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCCCCN5C(=O)C=CC5=O

InChI

InChI=1S/C68H100N12O14S/c1-13-43(6)58(51(92-11)39-55(84)79-36-21-25-50(79)59(93-12)44(7)60(85)74-49(63-70-34-37-95-63)38-45-22-16-14-17-23-45)78(10)64(88)57(42(4)5)76-65(89)68(8,9)77-67(91)94-40-46-27-29-47(30-28-46)72-61(86)48(24-20-33-71-66(69)90)73-62(87)56(41(2)3)75-52(81)26-18-15-19-35-80-53(82)31-32-54(80)83/h14,16-17,22-23,27-32,34,37,41-44,48-51,56-59H,13,15,18-21,24-26,33,35-36,38-40H2,1-12H3,(H,72,86)(H,73,87)(H,74,85)(H,75,81)(H,76,89)(H,77,91)(H3,69,71,90)/t43-,44+,48-,49-,50-,51+,56-,57-,58-,59+/m0/s1

InChIKey

OUOWRIRIGRPGBR-WUDDPNKVSA-N

Solubility

DMSO: 100 mg/ml (7453 mm)

Appearance

Solid

Shelf Life

0-4°C for short term (days to weeks), or -20°C for long term (months).

Shipping

Room temperature, or blue ice upon request.

Storage

Store at -20 °C, keep in dry and avoid sunlight.

Form

Solid

Biological Activity

MC-VC-PABC-Aur0101 is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.

MC-VC-PABC-Aur0101 is a highly effective peptide-drug conjugate (PDC) that combines the targeted delivery of a cytotoxic agent, auristatin 0101, with the specificity of a peptide linker. One of its key applications is in targeted cancer therapy. The conjugate uses a cleavable valine-citrulline (VC) linker, which is specifically cleaved by enzymes present in the tumor microenvironment. This enables the selective release of auristatin 0101 within the tumor cells, where it disrupts microtubule formation, leading to cell cycle arrest and apoptosis. This selective targeting reduces systemic toxicity and enhances the therapeutic effect on cancer cells.

Another significant application of MC-VC-PABC-Aur0101 is in drug delivery optimization. The addition of a peptide component enables the conjugate to selectively bind to cancer cells that overexpress specific receptors, while the cleavable VC linker ensures that the cytotoxic agent is only activated once it reaches the tumor site. This approach allows for prolonged circulation in the bloodstream, enhancing the pharmacokinetics of the drug and improving its accumulation at the tumor site. As a result, the therapeutic agent is delivered more efficiently and with greater specificity than conventional chemotherapy.

MC-VC-PABC-Aur0101 also has potential in combination cancer therapies. When used in combination with other therapeutic agents, such as immune checkpoint inhibitors or chemotherapeutic drugs, this conjugate can provide a synergistic effect. The targeted delivery of auristatin 0101 to tumor cells can enhance the efficacy of other treatments by promoting more localized and potent cell killing. Additionally, the use of MC-VC-PABC-Aur0101 in combination with immune-modulating therapies can help overcome tumor resistance mechanisms, improving the overall treatment response.

Finally, MC-VC-PABC-Aur0101 is a promising tool for personalized medicine. The peptide component can be engineered to target specific tumor markers or receptors, allowing for the customization of therapies based on the individual patient's cancer profile. This approach enhances the precision of the treatment, ensuring that the cytotoxic drug is delivered to the appropriate tumor cells while minimizing side effects. Personalized applications of MC-VC-PABC-Aur0101 hold great potential for improving patient outcomes in precision oncology.